Using AI to improve MRI for breast cancer screening and diagnosis
Peking University People's Hospital Radiology
Peking University People's Hospital · NCT05243121
This study is testing if using advanced AI technology can make breast MRI scans quicker and still accurately find cancer in women with certain symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Sex | Female |
| Sponsor | Peking University People's Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05243121 on ClinicalTrials.gov |
What this trial studies
This study utilizes Convolutional Neural Networks to analyze multiparametric breast MRI images for the classification of contrast-enhancing lesions. It aims to develop an abbreviated MRI protocol that reduces examination time while maintaining diagnostic accuracy for breast cancer in Chinese women. The study will include patients with specific clinical symptoms and will follow up for at least six months to confirm diagnosis outcomes. The goal is to enhance the efficiency of breast cancer screening and diagnosis through advanced imaging techniques.
Who should consider this trial
Good fit: Ideal candidates are women with clinical symptoms suggestive of breast cancer who are undergoing a full sequence breast MRI examination.
Not a fit: Patients who have previously received breast treatments or have contraindications for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to quicker and more accurate breast cancer screenings, improving early detection rates.
How similar studies have performed: Other studies have shown promise in using AI for medical imaging, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinical symptoms (define as palpable mass, nipple discharge, asymmetric thickening or nodules, and abnormal skin changes) * Patients undergoing full sequence BMRI examination * Through the follow-up database, at least 6 months of follow-up results can be obtained to determine whether the diagnosis result is negative/benign/malignant; for patients who need pathological biopsy, the pathological biopsy results shall prevail to determine the lesion benign/malignant Exclusion Criteria: * The breast had received radiotherapy, chemotherapy, biology and other treatments before BMRI. * There are contraindications for breast-enhanced MRI examinations such as allergy to contrast agents. * A prosthesis is implanted in the affected breast. * Patients during lactation or pregnancy
Where this trial is running
Beijing, Beijing
- Peking university people's hospital — Beijing, Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Yi Wang, doctor
- Email: wangyi@pkuph.edu.cn
- Phone: 86+010-88325813
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Neoplasms, Magnetic Resonance Imaging, breast neoplasms, magnetic resonance imaging, screening, deep learning, machine learning